Skip to main content

Michael M. Henry, MD

Edit Profile

Areas of Expertise

  • Benign Blood Disorder
  • Histiocytosis
  • Hodgkin Lymphomas
  • Liquid Tumors
  • Non-Hodgkin Lymphomas
  • Pediatric Hematology
  • Pediatric Oncology

Office

Main Hospital & Emergency Department
1919 E. Thomas Rd., Phoenix, Arizona 85016
602-933-1000

About Michael M. Henry, MD

Clinical interests: Dr. Henry is a member of the Liquid Tumor Team in the Center for Cancer and Blood Disorders, and he focuses on Hodgkin and Non-Hodgkin Lymphomas and the Histiocytic Disorders. He also has significant experience with benign hematological disorders.

Educational interests: The Center for Cancer and Blood Disorders sees a remarkable variety of patient diagnoses and a growing collaboration with researchers both inside and outside the hospital. We wanted to share this experience with trainees and to contribute to the next generation of pediatric hematologists/oncologists. In 2005, Dr. Henry started to develop a 3-year Pediatric Hematology/Oncology Fellowship Training Program, and the Program became accredited by the ACGME in 2008. Our first class of fellows started in the Program in 2010, and we celebrated our first graduates of the Program in June 2013.

Dr. Henry also spends time teaching and developing part of the medical school curriculum at the University of Arizona College of Medicine - Phoenix, and he welcomes medical students from numerous institutions into his outpatient clinic on a regular basis. In addition, Dr. Henry enjoys delivering core educational didactic sessions to the residency program at Phoenix Children's Hospital.

Research interests: Dr. Henry is currently studying the possible therapeutic benefit of non-steroidal anti-inflammatory drugs in the treatment of Langerhans Cell Histiocytosis. He also is mentoring a medical student from the University of Arizona in the study of the effects of obesity during treatment and eventual outcome in patients with Hodgkin lymphoma.

Share this page

Locations

Education & Training

Board Certification

Pediatric Hematology/Oncology; General Pediatrics

Medical School / Education

Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA

Residency

(Pediatrics) Al Dupont Hospital of Children/Thomas Jefferson University Hospital, Wilmington, DE

Fellowship

(Hematology/Oncology) Children's National Medical Center, Washington, D.C.

Academic Affiliations

Assistant Professor of Clinical Pediatrics, Department of Child Health, University of Arizona College of Medicine, Phoenix, Arizona; Assistant Professor of Pediatrics, Department of Pediatrics, Mayo College Of Medicine, Rochester, Minnesota; Assistant Professor of Pediatrics, Department of Pediatrics, Creighton University School of Medicine, Phoenix, Arizona

Professional Affiliations

Children's Oncology Group, American Society of Pediatric Hematology/Oncology; Histiocyte Society

Awards

  • Faculty Teacher of the Year (Phoenix Children's Hospital) 2005-2006

Research & Publications

Padman R, Henry M. The use of BiPAP in the treatment of the acute chest syndrome of sickle cell disease. Delaware Medical Journal. 76(5):119-203 (2004).

Henry M, Driscoll C, Miller M, Chang T, Minniti C. Pseudo tumor cerebri in children with sickle cell disease: A case series. Pediatrics113(3):e265-e269 (2004).

Mitchell S A, Brown K B, Henry M M, Mintz M, Catchpoole D, LaFleur B,Stephan D A.Inter- Platform comparability of micro arrays in acute lymphoblastic leukemia. BMC Genomics
5:71-77(2004).

Mintz M B, Sowers R, Brown K M, Hilmer S C, Mazza B, Huvos A G, Meyers P A, Lafleur B, McDonough W S, Henry M M, Ramsey K E, Antonescu C R, Chen W, Healey J H, Daluski A, Berens M E, Macdonald T J, Gorlick R, Stephan D A. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Research 65(5):1748-54(2005).

Harris R E, Termuhlen A M, SmithLM, Lynch J, Henry M M, Perkins S L, Gross T G, Warkentin P, Vlachos A, Harrison L, Cairo M S. Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children's Oncology Group Study A 5962. Blood and Bone Marrow Transplantation. Feb;17(2):249-58 (2011).

Kasem A J, Bulloch B, Henry M, M D, ShahK ,Dalton H. Procalciton in asa marker of bacteremia in children with fever and a central venous catheter presenting to the Emergency Department. Pediatric Emergency Care 28(10):1-5(2012).

Johnson K, Notrica D M, Carpentieri D, Jaroszewski D, Henry M M. Successful treatment of recurrent pediatric inflammatory myofibroblastictumor in a single patient with a novel chemotherapeutic regimen containing celecoxib. J Pediatr Hematol Oncol Jul; 35(5):414-6 (2013).

Chellapandian D, Das R, Zelley K, Wiener S J, Zhao H, Teachey D T, Nichols K E; EBV-HLH Rituximab Study Group. Treatment of Epstein Barr virus- induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeuticregimens. Br J Haematol Aug; 162(3):376-82(2013).

Abstracts

2009
Barrett D, Wey P ,Henry M, Pasztor L ,Dickman P, DeMello D. Blastic plasma cytoiddendritic cell leukemiaina child; case report and literature review. Poster presentation, XXII International Symposiumon Technological Innovations in Laboratory Hematology, Las Vegas,NV.

2010
Nelmes, Guo D, O'Sullivan M, Henry M, Fong A, Kiiveri H, Stone G, Kadupitige SR, Gaeta B, Bain M, Dahl N, Schuster J, Catch poole DR. Increased ribosomal protein L38 expression is indicativeof CD34+ cells present in childhood acute lymphoblastic leukaemia. Poster presentation, Lorne Cancer Conference, PhillipIsland, Victoria, Australia.

2011
Henry M, Dickman P.The expression of COX-2 in Langerhans Cell Histiocytosis. Poster presentation, The 27th Meeting of the Histiocyte Society (Vienna, Austria), October 2011

2011
Henry M. Hematophago cytic lymphohistiocytosis in the Native American Population- Experience at Phoenix Children's Hospital. Poster presentation, The 27th Meeting of the Histiocyte Society(Vienna, Austria), October 2011.

2014
Tomboc P, Henry M. Time to Antibiotic Administration for Febrile, Neutropenic Patients is Significantly Reduced by Using a Clinical Pathway in the Emergency Department. Poster Presentation, 27th Annual Meeting of the American Society of Pediatric Hematology/Oncology, Chicago, IL.

Lymphoma/Leukemia; Lymphoproliferative Disease; Histiocytic Disorders; Benign Hematology; Technology in the Workplace<br/>